Truist analyst Richard Newitter raised the firm’s price target on Stryker (SYK) to $400 from $392 and keeps a Hold rating on the shares. The company’s Investor Day showcased why Stryker should remain one of the higher quality large-cap MedTechs with “muscle” and continue delivering annual operating leverage, the analyst tells investors in a research note. Truist adds however that it remains in neutral as the firm prefers large-caps with faster earnings and revenue growth profiles.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker price target raised to $456 from $452 at Wells Fargo
- Stryker’s Strategic Growth Plans and Market Leadership Reinforce Buy Rating
- Stryker’s Strategic Growth and Innovation Drive: Buy Rating Affirmed
- Stryker’s Robust Growth Trajectory and Strategic Initiatives Justify Buy Rating
- Stryker’s Strong Market Position and Growth Potential Justify Buy Rating with $410 Price Target